Clearbridge Health (SGX:1H3) narrowed its attributable loss in the first half of 2025 to SG$1.4 million from SG$2.2 million a year earlier, according to a Thursday filing with the Singapore Exchange.
Loss per share stood at SG$0.0008 compared with SG$0.0038 in the comparable period.
Revenue was up 8% year over year to SG$4.9 million from SG$4.5 million, mainly due to increased revenue from renal care services provided in the Philippines.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。